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Background-—Ischemic preconditioning (IPC) and ischemic postconditioning (IPoC) are currently among the most efﬁcient
strategies protecting the heart against ischemia/reperfusion injury. However, the effect of IPC and IPoC on functional recovery
following ischemia/reperfusion is less clear, particularly with regard to the speciﬁc receptor-mediated signaling of the
postischemic heart. The current article examines the effect of IPC or IPoC on the regulation and coupling of b-adrenergic receptors
and their effects on postischemic left ventricular function.
Methods and Results-—The b-adrenergic signal transduction was analyzed in 3-month-old Wistar rats for each of the intervention
strategies (Sham, ischemia/reperfusion, IPC, IPoC) immediately and 7 days after myocardial infarction. Directly after the infarction
a cardioprotective potential was demonstrated for both IPC and IPoC: the infarct size was reduced, apoptosis and production of
reactive oxygen species were lowered, and the myocardial tissue was preserved. Seven days after myocardial ischemia, only IPC
hearts showed signiﬁcant functional improvement. Along with a deterioration in fractional shortening, IPoC hearts no longer
responded adequately to b-adrenergic stimulation. The stabilization of b-adrenergic receptor kinase-2 via increased phospho-
rylation of Mdm2 (an E3-ubiquitin ligase) was responsible for desensitization of b-adrenergic receptors and identiﬁed as a
characteristic speciﬁc to IPoC hearts.
Conclusions-—Immediately after myocardial infarction, rapid and transient activation of b-adrenergic receptor kinase-2 may be an
appropriate means to protect the injured heart from excessive stress. In the long term, however, induction and stabilization of
b-adrenergic receptor kinase-2, with the resultant loss of positive inotropic function, leads to the functional picture of heart failure.
( J Am Heart Assoc. 2017;6:e006809. DOI: 10.1161/JAHA.117.006809.)
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T he long-term prognosis of an acute myocardial infarctionis determined both by the extent of the resultant
irreversible tissue damage and by the reconstruction pro-
cesses that are immediately triggered, which are referred to
as cardiac remodeling. Short series of repetitive ischemia/
reperfusion cycles (IR), which are described as ischemic
preconditioning (IPC) and ischemic postconditioning (IPoC),
are currently among the most efﬁcient strategies for myocar-
dial protection.1,2 Both interventions share some signaling
pathways, although they are applied at opposing time points
of the ischemic period.3 To what extent this protective
intervention also leads to a better prognosis over the long
term depends fundamentally on its effect on the remodeling
of the postischemic myocardium.
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ORIGINAL RESEARCH
In the classical in vivo IPC and IPoC models, a reduction in
the size of the infarct is chosen as the relevant end point in
most cases even though this was often not accompanied by a
corresponding functional recovery.4,5 However, no informa-
tion can be gleaned about long-term functional improvements
or positive remodeling using these short-term models.
Therapeutically, application at the time of reperfusion is an
appropriate intervention option, meaning that in routine
clinical practice IPoC is the preferred protective strategy.6,7
However, the results from longitudinal human studies have
not provided a uniform picture of the efﬁcacy and safety of
IPoC.8 In 2013 a single-center study by Freixa et al showed
rather a signiﬁcant deterioration in the myocardial salvage
and the myocardial salvage index along with reduced pump
function 6 months after myocardial ischemia.9 These results
correspond to data published by Hahn et al from a multicen-
ter study of 700 patients (POST [Effects of Postconditioning
On Myocardial Reperfusion] trial, https://clinicaltrials.gov/
show/NCT00942500) that was conducted between 2009
and 2012, also showing no cardiprotective effect.10 Moreover,
recently published results of the DANAMI-3–iPOST (DANish
Study of Optimal Acute Treatment of Patients With ST-
elevation Myocardial Infarction, https://clinicaltrials.gov/
show/NCT01435408) trial have also demonstrated that
IPoC in addition to primary percutaneous coronary interven-
tion failed to signiﬁcantly reduce death from any cause or
hospitalization during a median follow-up of 38 months.11
It has already been shown for both IPC and IPoC that both
prior pharmacological interventions and preexisting diseases
(diabetes mellitus, chronic heart failure) can contribute to a
reduction in their cardioprotective potential. 12-14
What is not currently known, however, is the effect of both
intervention strategies on cardiac receptors, which, as
important components of the functional and structural
remodeling, are signiﬁcantly involved in the functional
preservation of the postischemic myocardium and thus play
a critical role in the efﬁciency of IPC or IPoC.15
The b-adrenergic receptor (b-AR) is primarily involved in
the maintenance and, where necessary, adaptation of cardiac
function. The density and the signaling of the cardiac b-ARs
change over the course of many cardiac diseases. In the
postischemic failing myocardium these changes are often
associated with signiﬁcant downregulation of the b-ARs. The
activation and intracellular coupling of the b1-AR, on the other
hand, can be inadequately elevated in the early postischemic
phase.16-18
The primary aim of this research was to study the effect of
IPC or IPoC on the remodeling of the b-adrenergic system and
their effects on the function of the postischemic myocardium.
A new signaling mechanism for the IPoC has been
identiﬁed that considerably reduces the coupling of b-ARs
independently of a reduction in the size of the infarction. The
resulting restriction in the positive inotropic functional reserve
induced a persistent cardiac dysfunction in the postcondi-
tioned myocardium.
Methods
The investigation conforms to the Guide for the Care and Use
of Laboratory Animals published by the US National Institutes
of Health (NIH Publication No. 85-23, revised 1996). The data
and analytic methods that support the ﬁndings of this study
are available from the corresponding author on request.
Langendorff Perfusion
Using the Langendorff technique, Krebs-perfused hearts from
3-month-old female Wistar rats were subject to 45 minutes of
global ischemia and then reperfused for 120 minutes (IR). The
IR protocol was either supplemented by IPC (393 minutes of
no ﬂow—5 minutes of perfusion) or IPoC (3930 seconds of
perfusion—30 seconds of no ﬂow), and the corresponding
functional recovery and the extent of the resultant tissue
damage were compared to the values for a normoxic control
group (Figure 1A). For this purpose, rats were anesthetized by
isoﬂurane and killed by cervical dislocation. Their hearts were
rapidly excised, and the aortas were cannulated for retrograde
perfusion with a 16-gauge needle connected to a Langendorff
perfusion system. A polyvinyl chloride balloon was inserted
Clinical Perspective
What Is New?
• Ischemic preconditioning and ischemic postconditioning are
very efﬁcient clinically applied strategies that protect the
heart against ischemia/reperfusion injury.
• What remains unknown, however, is their effect on the
function of cardiac receptors, which are signiﬁcantly
involved in the functional and structural remodeling of the
postischemic myocardium.
• Here, we have been able to demonstrate that, unlike
ischemic preconditioning, the application of ischemic post-
conditioning by inducing b-adrenergic receptor kinase-2
leads to desensitization of b-adrenergic receptors, which in
turn induces cardiac dysfunction with restricted inotropic
functional reserve.
What Are the Clinical Implications?
• The ﬁndings of this study not only provide a possible
explanation for the previously disappointing long-term
clinical trials of ischemic postconditioning but also identify
the postconditioned heart as another indication for the
therapeutic use of prospective b-adrenergic receptor
kinase-2 inhibitors.
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into the left ventricle (LV) through the mitral valve and held in
place by a suture tied around the left atrium. The other end of
the tubing was connected to a pressure transducer for
continuous measurement of LV pressure. A second
transducer connected to the perfusion line just before the
heart was used to measure coronary perfusion pressure.
Hearts were perfused with an oxygenated saline medium
containing (in mmol/L) 140 NaCl, 24 NaHCO3, 2.7 KCl, 0.4
NaH2PO4, 1 MgCl2, 1.8 CaCl2 and 5 glucose, gassed with 95%
O2 and 5% CO2, pH 7.4. After attachment to the Langendorff
system, hearts were allowed to stabilize for at least 20 min-
utes. The intraventricular balloon was inﬂated to give a
diastolic pressure of 10 mm Hg. The ﬂow was adjusted to
give a perfusion pressure of 50 mm Hg. To avoid differences
in oxygen supply due to changes in the coronary resistance,
hearts were perfused at a constant ﬂow. The perfusion system
was constantly kept at a temperature of 37°C throughout the
whole experiment.15 As a pharmacological inhibitor of protein
kinase C (PKC), chelerythrine chloride (1 lmol/L, Merck
Millipore, Darmstadt, Germany; product #220285) was
applied from the onset of reperfusion.
Measurement of Lactate Dehydrogenase Activity
The lactate dehydrogenase (LDH) release of Langendorff
hearts was measured in the perfusate, which was collected
for 60 seconds after 5 minutes of reperfusion. LDH activity
was determined using a colorimetric LDH assay kit (Abcam,
Cambridge, UK). In brief, LDH reduces NAD to NADH, which
then interacts with a speciﬁc probe to generate color at
450 nm. The intensity of the color is directly proportional to
the LDH activity (U/L) in each sample. Fifty-microliter
samples were incubated with LDH substrate mix and
measured immediately at OD 450 nm on a microplate
reader in a kinetic mode for 45 minutes at 37°C. LDH
activity in each sample was calculated according to a
standard curve.
Measurement of Superoxide
Fifteen minutes after the start of reperfusion, left ventricular
tissue was prepared for cryosectioning by freezing in Tissue-
Tek OCT Compound (Sakura Finetek Germany GmbH, Staufen,
Germany). To perform dihydroethidium staining, cryoslices of
the LV were incubated with the ﬂuorescent probe dihy-
droethidium (dissolved in 19 PBS) for 10 minutes at 37°C in
a light-protected humidity chamber, then ﬁxed with Dako
Fluorescent Mounting Medium (Dako North America Inc,
Carpinteria, CA). Sections were imaged by ﬂuorescence
microscopy (LSM 510 META; Carl Zeiss, Jena, Germany)
using an excitation wavelength of 488 nm; emission was
recorded at 540 nm.19
Analysis was performed by digital image analysis using
Leica Confocal Software Lite Version (LCS Lite; Leica, Wetzlar,
Germany). The mean ﬂuorescence intensity of n=6 ventricles
was used to quantify the extent of superoxide.
Figure 1. Study designs and treatment protocols. A, Stimula-
tion of b-ARs at the end of a 2-hour reperfusion in the Langendorff
model. B, Stimulation of b-ARs 7 days after infarction in the
working heart model. C, Cardiomyocytes were isolated from IPC
or IPoC hearts and cultured for 24 hours. Cell shortening was
determined before and after stimulation with ISO using a cell-edge
detection system. D, Perfusion of IPoC hearts 7 days after an
infarction. After 10 minutes’ infusion with paroxetine, the CO was
measured continuously for 5 minutes with additional stimulation
using ISO. b-AR indicates b-adrenergic receptor; CO, cardiac
output; IPC, ischemic preconditioning; IPoC, ischemic postcondi-
tioning; ISO, isoproterenol.
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Immunohistochemistry Analysis of Active
Caspase-3 and Connexin 43
Subsequent to the particular reperfusion time, Langendorff-
perfused hearts were ﬁxed after snap-freezing and sectioned
using a cryostat (section thickness 10 lm). Brieﬂy, slides
were rehydrated in PBS for 15 minutes and then blocked with
bovine serum albumin (5%) for 1 hour. Primary antibodies
against active caspase-3 or connexin 43 were diluted 1:100 in
PBS/Tween containing 2.5% bovine serum albumin and
incubated for 1 hour at room temperature. Slides were
washed 20 minutes with PBS/Tween and incubated with an
Alexa Fluor-488 coupled secondary antibody (Molecular
Probes, Eugene, OR) for 1 hour. The visualization and
quantiﬁcation of the ﬂorescence were carried out using a
ﬂorescence microscope (Till Photonics, Gr€afelﬁng, Germany).
Rat Model of Ischemia and Reperfusion In Vivo
In brief, female Wistar-Hannover rats weighing 210 to 265 g
were anesthetized by intraperitoneal injection of 60 mg/kg
sodium pentobarbital (Euthasol, Produlab Pharma b.v., Raams-
donksveer, the Netherlands). Animals were intubated and
mechanically ventilated (Model 683, Harvard Apparatus, Hol-
liston, MA) with room air in a volume of 6.2 mL/kg and a
frequency of 725 breaths/min according to body weight.
Rats were placed in a supine position on a heating pad to
maintain body core temperature in physiological range
(37.01.0°C). Body surface ECG was monitored throughout
the experiments (Haemosys, Experimetria Inc, Budapest,
Hungary). Left anterior descending coronary artery occlusion
was induced by a left thoracotomy. A 5-0 Prolene suture
(Ethicon, Johnson & Johnson Kft Hungary, Budapest, Hungary)
was placed around the left anterior descending artery and a
small plastic knob, which was threaded through the ligature and
placed in contact with the heart, was used for making occlusion
for 30 minutes. Animals for the IPC group were subjected to 3
cycles of 3 minutes of ischemia followed by 5 minutes of
reperfusion before a 30-minute test ischemia; IPoC was
performed after test ischemia by using 3 cycles of 30 seconds
of reperfusion/30 seconds of ischemia. The presence of
ischemia was conﬁrmed by the appearance of ST segment
elevation and ventricular arrhythmias. After 30 minutes of
ischemia or the postconditioning protocol, the occlusion was
released, and the suture was removed from the heart.
Restoration of blood ﬂow was conﬁrmed by the appearance
of arrhythmias observed in the ﬁrst minutes after the onset of
reperfusion. Then the chest was closed in layers with a 4-0
Monocryl suture (Ethicon, Johnson & Johnson Kft Hungary,
Budapest, Hungary), and 0.3 mg/kg nalbuphin (Nalbuphin
Orpha, Torrex Chiesi Pharma GmbH, Vienna, Austria) was given
subcutaneously to alleviate postoperative pain. Rats were
allowed to recover for 7 days after coronary occlusion.
Sham-operated animals were treated with the same procedure
except occlusion of the coronary artery (Figure 1B). The
surgical procedure was performed according to previous
publications.20,21
Transthoracic Echocardiography
Cardiac morphology and function were also assessed by
transthoracic echocardiography 7 days after the induction of
ischemia/reperfusion injury or sham operation. Echocardio-
graphy was performed as described previously.22 Brieﬂy, rats
were anesthetized with sodium pentobarbital (Euthasol,
40 mg/kg body weight, intraperitoneally), the chest was
shaved, and the animal was placed in supine position onto a
heating pad. Two-dimensional and M-mode echocardiographic
examinations were performed in accordance with the criteria
of the American Society of Echocardiography with a Vivid 7
Dimension ultrasound system (General Electric Medical
Systems, Waukesha, WI) using a phased-array 5.5- to 12-
MHz transducer (10S probe). Data of 3 consecutive heart
cycles were analyzed (EchoPac Dimension Software, General
Electric Medical Systems) and then the mean values of the 3
measurements were calculated and used for statistical
evaluation. Systolic and diastolic wall thicknesses were
obtained from parasternal short-axis view at the level of the
papillary muscles. The left ventricular diameters were mea-
sured by means of M-mode echocardiography from short-axis
views between the endocardial borders. Functional parame-
ters including fractional shortening and ejection fraction were
calculated on short-axis view images.
Measurement of Functional Parameters of
Hearts: Working Heart Perfusion
After echocardiographic examinations, rat hearts were iso-
lated and prepared for working heart perfusion according to
Neely et al.23-25 Hearts were perfused at 37°C with freshly
prepared Krebs-Henseleit bicarbonate buffer containing (in
mmol/L) NaCl 118, KCl 4.3, CaCl2 2.4, NaHCO3 25, KH2PO4
1.2, MgSO4 1.2 and glucose 11.1, gassed with 95% O2 and 5%
CO2. Preload (17 cm H2O) and afterload (100 cm H2O) were
kept constant throughout the experiments. Coronary ﬂow was
measured by collecting efﬂuent from the right atrium by a
measuring cylinder for 1 minute, aortic ﬂow was measured by
a calibrated rotameter (KDG Flowmeters, Sussex, England),
and cardiac output (CO) was calculated as the sum of aortic
ﬂow and coronary ﬂow. Ventricular pressure was measured by
means of a pressure transducer (B. Braun, Melsungen,
Germany) connected to a small polyethylene catheter inserted
into the LV through the left atrial cannula. Left ventricular
developed pressure (LVDP) was calculated as peak systolic
pressure minus LV end-diastolic pressure, positive and
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negative ﬁrst derivatives of left ventricular pressure (dp/dt),
and LV end-diastolic pressure were also deﬁned. Heart rate
was derived from the LV pressure curve.
Measurement of Cardiac Troponin I Release in
Plasma
Plasma samples were collected into heparinized tubes
(Sarstedt, N€umbrecht, Germany) from the femoral vein at
the 60th minute of reperfusion, and plasma was separated to
determine cardiac troponin I (TnI) release after acute
myocardial infarction. Plasma TnI concentration was deter-
mined by a conventional ELISA kit (Life Diagnostics, Inc, West
Chester, PA) according to the recommendations of the
manufacturer. Brieﬂy, plasma samples were diluted 4 to 40
times according to the treatment protocol (ie, sham or
ischemic) and to previous preanalyses to get absorbances in
the range of standard absorbances. Diluted samples were
allowed to react simultaneously with 2 antibodies against rat
TnI (1 is immobilized on the microtiter wells, and the other is
conjugated to horseradish peroxidase [HRP] in soluble phase),
resulting in TnI being sandwiched between the solid phase
and HRP-conjugated antibodies. After 1 hour of incubation at
room temperature on a plate shaker, the wells were washed
with wash solution to remove unbound HRP-conjugated
antibodies. A solution of tetramethylbenzidine, a HRP sub-
strate, was then added and incubated for 20 minutes,
resulting in the development of a blue color. The color
development was stopped by addition of 1N HCl, which
changed the color to yellow. The concentration of TnI was
proportional to the absorbance at 450 nm.
Determination of Infarct Size
After 120 minutes of reperfusion, hearts were isolated for
infarct size measurements. Hearts were perfused in a
Langendorff perfusion system with 37°C Krebs-Henseleit
buffer to remove blood from the coronary vessels. After
5 minutes of perfusion, the risk area was reoccluded, and
hearts were perfused with 4 mL of 0.1% Evans blue dye
through the ascending aorta. Following Evans staining, hearts
were cut into 5 transverse slices and incubated in 1%
triphenyltetrazolium chloride for 10 minutes at 37°C followed
by formalin ﬁxation for 10 minutes. Digital images were taken
from both surfaces of heart slices by a Nikon DSLR camera
(Nikon Corporation, Tokyo, Japan). Planimetric evaluation was
carried out to determine infarct size using InfarctSizeTM
software version 2.5, (Pharmahungary, Szeged, Hungary26).
Western Blot
Total protein was extracted from the LV using Cell Lysis Buffer
(109) (Cell Signaling, Danvers, MA) according to the
manufacturer’s protocol. Brieﬂy, the homogenate was cen-
trifuged at 14 000g at 4°C for 10 minutes, and supernatant
was treated with Laemmli buffer. Protein samples were loaded
on NuPAGE Bis-Tris Precast gels (8%, 10%; Life Technology,
Darmstadt, Germany) and subsequently transferred onto
nitrocellulose membranes. Blots were incubated with 1 of
the following antibodies: anti-b1-AR (V-19) (Santa Cruz
Biotechnology, Inc, Heidelberg, Germany; product sc-568),
anti-b2-AR (H-73) (Santa Cruz Biotechnology, Inc, Heidelberg,
Germany; product sc-9042), anti-b-adrenergic receptor
kinase-2 (anti-GRK2; Sigma-Aldrich, Taufkirchen, Germany;
product G0296), anti-GRK2 phospho S29 (Abcam plc, Cam-
bridge, UK; product ab58520), anti-b-arrestin1/2 (New Eng-
land Biolabs GmbH, Frankfurt am Main, Germany; product
#4674), anti-MDM2/HDM2 (R&D Systems, Wiesbaden, Ger-
many; AF1244), anti-MDM2 phospho Ser166 (New England
Biolabs GmbH, Frankfurt am Main, Germany; product #3521),
anti-PI3 kinase p110a (Becton Dickinson GmbH, Heidelberg,
Germany; product #611398), and anti-GAPDH (Merck Milli-
pore, Darmstadt, Germany; product CB1001). Secondary
antibodies (HRP-conjugated) directed against rabbit IgG or
mouse IgG were purchased from Afﬁnity Biologicals (Ancaster,
ON, Canada; product SAR-APHRP, GAM-APHRP). In order to
detect b1-AR dimers, samples were treated with nonreducing
Laemmli buffer and loaded on a 10% NuPAGE Bis-Tris Precast
gel.
Densitometry of immunoblot bands was carried out using
Quantity One software from Bio-Rad Laboratories (Hercules,
CA). The intensities of the target proteins were normalized to
that of GAPDH of the same sample.
RNA Isolation and Real-Time Reverse-
Transcriptase Polymerase Chain Reaction
Total RNA was isolated from the LV using peqGold TriFast
(peqlab, Biotechnologie GmbH, Erlangen, Germany) according
to the manufacturer’s protocol. To remove genomic DNA
contamination, RNA samples were treated with 1 U DNase/
lg RNA (Invitrogen, Karlsruhe, Germany) for 15 minutes at
37°C. One microgram of total RNA was used in a 10-lL
reaction to synthesize cDNA using Superscript RNaseH
Reverse Transcriptase (200 U/lg RNA, Invitrogen, Karlsruhe,
Germany) and oligo-dTs as primers. Reverse transcriptase
reactions were performed for 50 minutes at 37°C. Real-time
quantitative polymerase chain reaction was performed using
MyiQ detection system (Bio-Rad, Munich, Germany) in
combination with the iTaq Universal SYBR Green Real-Time
PCR Supermix (Bio-Rad, Munich, Germany). The thermal
cycling program consisted of initial denaturation in 1 cycle
of 3 minutes at 95°C, followed by 45 cycles of 30 seconds at
95°C, 30 seconds at the individual annealing temperature for
each primer, and 30 seconds at 72°C. Primers used for
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determination had the following sequences: HPRT forward
CCA GCG TCG TGA TTA GTG AT, HPRT reverse CAA GTC TTT
CAG TCC TGT CC, b1-AR forward GGC GCT CAT CGT GCT GCT
CA, b1-AR reverse AGG CAC CAC CAG CAG TCC CA, b2-AR
forward GCT TCT GTG CCT TCG CCG GT, b2-AR reverse AGC
CTT CCA TGC CAG GG GCT, b3-AR forward GGT TGG GCT ATG
CCA ACT CT, b3-AR reverse CCT GTT GAG CGG TGA GTT CT,
GRK2 forward GCT CTT CAA GTT GTT GCG GG, GRK2 reverse
AAA CCT TCC AGC AGG GAT CG. Quantiﬁcation was
performed as described before.27
Isolation and Culture of Cardiomyocytes From the
LV
Heart muscle cells from the LV were isolated from 3-month-
old Wistar rats. Brieﬂy, hearts were excised and transferred
rapidly to ice-cold saline and mounted on the cannula of a
Langendorff perfusion system. Heart perfusion and subse-
quent steps were all performed at 37°C. First, hearts were
perfused in a noncirculating manner for 5 minutes at 10 mL/
min. Thereafter, perfusion was continued with recirculation
using 50 mL perfusate supplemented with 0.06% (w/v) crude
collagenase and 25 lmol/L CaCl2 at 5 mL/min for 25 min-
utes. Then, the LV was dissected from the RV, minced, and
incubated for 5 minutes in medium with 1% (w/v) bovine
serum albumin under 5% CO2 and 95% O2. The resulting cell
suspension was ﬁltered through a 200-lm nylon mesh.
Filtered cells were washed twice by centrifugation and
resuspended in perfusate with a stepwise increase in CaCl2
to 0.2 and 0.5 mmol/L. After further centrifugation, cells
were resuspended in serum-free culture medium and plated in
35-mm culture dishes (Falcon, type 3001).28
Isolated cardiomyocytes were then incubated with siRNA
against GRK2 (Qiagen GmbH, Hilden, Germany, product
Rn_Adrbk1_1), siRNA against b-arrestin1 (Qiagen GmbH,
Hilden, Germany, product Rn_Arrb1_2), or siRNA against
b-arrestin2 (Qiagen GmbH, Hilden, Germany, product
Rn_Arrb2_1) for 24 hours. Paroxetine (LKT Laboratories, St.
Paul, MN) was used as a pharmacological inhibitor of GRK2.
Determination of Cell Contraction
Cell shortening was measured as described before in greater
detail.28 Brieﬂy, isolated cardiomyocytes were allowed to
contract at room temperature and analyzed using a cell-edge
detection system. Cells were stimulated via 2 AgCl electrodes
with biphasic electrical stimuli composed of 2 equal but
opposite rectangular 50-V stimuli of 0.5 milliseconds dura-
tion. Each cell was stimulated for 1 minute at a frequency of
2.0 Hz. Every 15 seconds contractions were recorded. The
mean of these 4 measurements was used to deﬁne the cell
shortening of a given cell. Cell lengths were measured via a
line camera (data recording at 500 Hz). Data are expressed as
cell shortening normalized to diastolic cell length (dL/L [%]).
Statistical Analysis
Data are presented as meanSD as indicated in the legends
of the ﬁgures and tables. All data sets were initially analyzed
by a Shapiro-Wilk test to analyze whether the data are
normally distributed. If this was the case, data were analyzed
either by paired or unpaired t-test depending on the study
design. If the 2 groups had different variances (as analyzed by
the Levene test), we calculated the P-value by a Welch test. In
the case that the data were not normally distributed, we
performed a Mann-Whitney test for unpaired samples or a
Friedman test for paired samples. In those ﬁgures in which
more than 2 groups were compared, we performed a 1-way
ANOVA with a subsequent Student-Newman-Keuls test for
post hoc analysis as long as the data were normally
distributed. If data were not normally distributed, we used a
Kruskal-Wallis test to decide whether differences between
groups occurred. A P-value of ≤0.05 is always indicated by an
asterisk to indicate that this was used as the threshold to
reject the null hypothesis. Statistical analysis was performed
by SPSS (IBM, Armonk, NY) version 22.0.
Results
Evidence of Cardiac Protection for IPC and IPoC
Algorithms Used on the Ex Vivo Perfused Heart
The efﬁciency of IPC and IPoC was analyzed in Langendorff
perfused hearts using the experimental protocol in Figure 1A.
LDH release, the formation of superoxide, and the proportion
of activated caspase-3 were signiﬁcantly elevated in the
hearts in the IR group compared with those in the normoxic
group (Figure 2A through 2C). All parameters were improved
by both IPC and IPoC. The cardioprotective potential of both
protocols was also reﬂected in the structural preservation
(connexin 43), whereas the short-term functional recovery
within the 120-minute reperfusion period did not improve
signiﬁcantly (Figure 2D and 2E).
Stimulation of b-ARs 2 Hours After Infarction in
the Langendorff Model
In another series of experiments the previously described
perfusion protocols (normoxia, IR, IPC, IPoC) were supple-
mented by a ﬁnal stimulation with isoproterenol (ISO,
10 nmol/L) for 5 minutes (Figure 1A). Both the ISO-induced
increase in the heart rate and the reduction in the coronary
resistance were equally pronounced in the 4 treatment
groups. A signiﬁcant increase in the LVDP was observed only
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in the hearts in the normoxia, IR, and IPC groups but,
unexpectedly, not in IPoC hearts (Table 1).
There were no differences observed in the LV expression of
the b1-AR in the Western blot among the comparator groups.
However, compared with normoxic control hearts, the
proportion of b1-AR dimers was signiﬁcantly reduced in the
myocardium of reperfused hearts regardless of the particular
protocol used (Figure 3A through 3C).
The b-adrenergic receptor kinases (GRKs), which mediate
the accumulation of b-arrestin by phosphorylating serine and
threonine residues on the intracellular domains of the
receptor, are critically involved in the regulatory mechanisms
for intracellular coupling of the b-ARs and, in turn, can prevent
activation of the Gs subunit or induce internalization of the
receptor.
The phosphorylation, and thus the activation, of GRK2 was
signiﬁcantly reduced in the hearts in the IR and IPC groups.
Consequently, the ratio of receptor dimers to phosphorylated
GRK2 did not differ from that of the hearts in the control
group. In contrast, in postconditioned hearts, the increased
proportion of phosphorylated GRK2 combined with the
signiﬁcant reduction in the b-AR dimers led to an imbalance,
which may be the underlying cause of the missing increase in
the LVDP following b-adrenergic stimulation (Figure 3A, 3D
through 3F, Table 1).
Signiﬁcance of PKC for GRK2 Phosphorylation in
the Postconditioned Heart
It has already been shown for PKC that it can effectively
contribute to the desensitization of G-protein-coupled recep-
tors via phosphorylation of GRK2.29 By inhibiting PKC using
chelerythrine chloride, the IPoC-induced phosphorylation of
GRK2 is signiﬁcantly reduced, and consequently, the ISO-
induced increase in the LVDP at the end of a 2-hour
reperfusion can be reestablished (Figure 3G and 3H).
Figure 2. Proof of cardiac protection for IPC and IPoC algorithms in a Langendorff model of myocardial ischemia and reperfusion. A, Five
minutes after the onset of reperfusion, the LDH level was determined in the perfusate as a surrogate parameter for tissue damage. B, After
15 minutes of reperfusion reactive oxygen species (ROS) were determined in the left ventricular myocardium using DHE staining. C,
Activation of caspase-3 was determined by immunohistochemistry after 120 minutes of reperfusion. D, The structural preservation of the
myocardium was qualitatively assessed using connexin 43 staining. E, Functional recovery was expressed as a percentage of the
preischemic LVDP. Data are meansSD of n=6 to 8 hearts. *P≤0.05 vs Nx, #P≤0.05 vs IR. DHE indicates dihydroethidium; IPC, ischemic
preconditioning; IPoC, ischemic postconditioning; IR, ischemia/reperfusion; LDH, lactate dehydrogenase; LVDP, left ventricular developed
pressure; Nx, normoxia.
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Effect of IR, IPC, and IPoC on the Size of the
Infarct and the Cardiac Function In Vivo
IPoC has already induced a speciﬁc remodeling of the
b-adrenergic signaling during the short-term reperfusion
ex vivo. It is certainly an important question whether IPoC also
affects the coupling of b-ARs over the long term in vivo (see
experimental protocol in Figure 1B). One hour after the onset of
reperfusion, the TnI plasma level was determined. Compared
with the sham group (1.10.8 ng/mL), the plasma samples
from the IR group had the highest concentrations of TnI at
104.333.6 ng/mL and were signiﬁcantly reduced by IPC to
32.833.9 ng/mL or by IPoC to 41.941.1 ng/mL (Fig-
ure 4A). The validity of TnI as a marker to determine the size of
the infarct in the IR model used here was demonstrated in a
separate group of animals. Plasma TnI values measured 1 hour
after infarction conﬁrm a reduction in the size of the infarct in
conditioned animals of the samemagnitude as that determined
using triphenyltetrazolium chloride staining in the correspond-
ing hearts 2 hours after starting reperfusion (Figure S1).
After 7 days the left ventricular morphology and function
were assessed using echocardiography. Fractional
shortening was 59.812% in the sham group, which was
signiﬁcantly reduced (42.910%) in the IR group. The
application of IPC improved the fractional shortening to
49.814%, whereas the hearts in the IPoC group only
achieved a value of 32.212%, which did not differ
statistically from the IR group (Figure 4B).
There were no signiﬁcant differences in the ventricular
geometry determined by echocardiography (Table S1) and the
wet weight analyzed postmortem (data not shown) between
the groups at the end of the experimental period.
Stimulation of b-ARs 7 Days After Infarction in
the Working Heart Model
After the 7 days had elapsed, the pump function and
hemodynamics of the hearts were recorded ex vivo in the
working heart model, ﬁrst at a basal level and again
immediately after stimulation with ISO (10 nmol/L) (Fig-
ure 1B). The basal CO, respectively the LVDP and dP/dtmax,
conﬁrmed the values for the function previously determined
by echocardiography and also identiﬁed the IPC as the only
cardioprotective application in terms of a medium-term
preservation of function. The 4 groups did not differ in terms
of their heart rates or the coronary ﬂow (Table 2).
After stimulation with ISO, a signiﬁcant increase was
recorded for the CO and the LVDP only for the sham-operated
hearts and the hearts in the IR and the IPC groups. IPoC
hearts were no longer able to adequately respond to the
b-adrenergic stimulus in terms of all contraction parameters
(Table 2).
On the other hand, the heart rate increased uniformly by
304% on average under ISO stimulation in all 4 treatment
groups. The coronary ﬂow also rose with the increase in the
hearts of the sham group (63%) about one and a half times as
high as that in the hearts of the IR, IPC, and IPoC groups,
which had a mean rise in the ﬂow of 423% and did not differ
from each another (Table 2).
Effect of IR, IPC, and IPoC on the Remodeling and
the Intracellular Coupling of Cardiac b-Receptors
The expression (mRNA and protein) of the b1- and b2-ARs was
signiﬁcantly reduced in the hearts in the IR, IPC, and IPoC
groups compared with the sham group 7 days after the
infarction with no differences seen among the groups.
Receptor dimers can no longer be detected under these
conditions. The expression of the b3-AR is stable postis-
chemia and was unaffected by either IPC or IPoC (Figure 5A
through 5D, for mRNA data; please see Figure S2). A
selective inﬂuence of IPoC on the expression of cardiac
b-ARs can therefore be excluded. This result was also
veriﬁed by measuring sodium-potassium-ATPase as a surro-
gate marker for membrane density, which in the
Table 1. Inﬂuence of IR, IPC, and IPoC on b-AR–Mediated
Effects 2 Hours After Myocardial Infarction
Heart Rate (beats/min)
Baseline ISO
Nx 24444 31826*
IR 23442 30548*
IPC 24624 31452*
IPoC 23060 30336*
Perfusion Pressure (mm Hg)
Baseline ISO
Nx 578 463*
IR 648 557*
IPC 6213 507*
IPoC 7218 6214*
LVDP (mm Hg)
Baseline ISO
Nx 10918 1267*
IR 8513 9812*
IPC 9120 10022*
IPoC 9424 9321
The heart rate increased and the perfusion pressure fell uniformly under ISO stimulation
in all 4 treatment groups. A signiﬁcant increase in the LVDP was observed only in hearts
of the Nx, IR, and IPC groups. Data are meansSD of n=6 to 8 hearts.
IPC indicates ischemic preconditioning; IPoC, ischemic postconditioning; IR, ischemia/
reperfusion; ISO, isoproterenol; LVDP, left ventricular developed pressure; Nx, normoxia.
*P≤0.05 vs baseline.
DOI: 10.1161/JAHA.117.006809 Journal of the American Heart Association 8
Postischemic Remodeling of b-Adrenergic Coupling Schreckenberg et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
postconditioned myocardium does not differ from IR or IPC
hearts (Figure 5K).
In hearts of the IR and IPC groups, GRK2 was signiﬁcantly
downregulated, meaning that the ratio of b-ARs to GRK2 was
unchanged compared to the hearts of the control group. In
IPoC hearts, on the other hand, signiﬁcant increases in GRK2
as well as its phosphorylated fraction were recorded. The
receptor/pGRK2 ratio was shifted 2.6 times toward GRK2,
which thus explains the reduced response of IPoC hearts to
b-adrenergic stimuli (Figure 5E through 5H).
The expression of GRK2 was positively correlated with
b-arrestin1/2 in all groups, meaning that desensitization of
the b-receptors in the IPoC hearts was synergistically
ampliﬁed (Figure 5J).
The high levels of GRK2 in the IPoC hearts cannot be
attributed to an increase in the mRNA expression but are
instead due to stabilization of the protein (Figure 5I).
Cardiomyocyte as the Cause of Dysfunction in
the IPoC Heart
Using the isolated cardiomyocyte model, the previously
described molecular and functional remodeling of the post-
conditioned myocardium can be conﬁrmed at a cellular level
(Figure 1C). Cardiomyocytes isolated from postconditioned
hearts showed no difference in basal cell shortening after 24-
hour culture compared to IPC myocytes, but their responsivity
to ISO was signiﬁcantly reduced with a simultaneous induc-
tion of GRK2 (Figure 6A and 6B). This ﬁnding suggests that
the limited inotropy of postconditioned hearts can be
attributed exclusively to remodeling of the b-adrenergic
signaling and not to structural remodeling processes of the
cardiomyocytes or the myocardium. Consequently, postcon-
ditioned hearts with simultaneous inhibition of GRK2 should
be able to achieve a positive inotropic response to ISO.
Figure 3. Inﬂuence of IR, IPC, and IPoC on b-adrenergic signaling 2 hours after starting reperfusion. A, Representative immunoblots
and quantiﬁcation by densitometric analysis of (B) b1-AR dimers (D, MW 95 kDa) and (C) b1-AR monomers (M, MW 50 kDa).
Quantiﬁcation of the (D) phosphorylated (p-GRK2) and (E) total GRK2 protein. F, The p-GRK2 to b1-AR (D) ratio was calculated for
each animal, and group means were expressed as fold change of Nx. Data are meansSD of n=6 hearts. *P≤0.05 vs Nx, #P≤0.05 vs
IPC. The signiﬁcance of PKC for GRK2 phosphorylation. G, ISO-induced inotropic response of IPoC hearts perfused with the PKC
inhibitor CEC. H, The effect of PKC inhibition on GRK2 phosphorylation in IPoC hearts. Immunoblot bands were normalized to GAPDH
and expressed as a percentage of Nx. Data are meansSD of n=6 hearts. *P≤0.05 vs IPoC. CEC indicates chelerythrine chloride; D,
dimer; GAPDH, Glyceraldehyde 3-phosphate dehydrogenase; GRK2, G protein-coupled receptor kinase 2; IPC, ischemic preconditioning;
IPoC, ischemic postconditioning; IR, ischemia/reperfusion; ISO, isoproterenol; M, monomer; Nx, normoxic; p-GRK2, phosphorylated
GRK2; PKC, protein kinase C; b1-AR, b1-adrenergic receptor.
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This hypothesis was tested experimentally using the
working heart model by perfusing postconditioned hearts
after 7 days’ reperfusion ﬁrst with the GRK2 inhibitor
paroxetine for 10 minutes and then stimulating them with
ISO (Figure 1D).
With inhibition of the GRK2, the CO of IPoC hearts rose by
5530% on average during the b-adrenergic stimulation. In
the direct comparison, ISO induced only a moderate increase
of 144% in the CO of IPoC hearts, which were not perfused
with paroxetine (Figure 6C).
The functional relevance of GRK2 (and b-arrestin) was
conﬁrmed in all experimental models (isolated cardiomy-
ocytes, isolated perfused hearts) using selective knockdown
with siRNA and/or pharmacological inhibition. The ISO
concentration used is based on the dose-response curves
determined on isolated normoxic cardiomyocytes (Figures S3
through S6).
Signaling Mechanisms Underlying GRK2
Induction
GRK2 is regulated both at the transcription level and to a
considerable degree via its degradation, in which the E3-
ubiquitin ligase Mdm2 is primarily involved.
Figure 4. Inﬂuence of IR, IPC, and IPoC on infarct size and
cardiac function in vivo. A, Plasma levels of cardiac troponin I
(TnI) were determined 1 hour after the onset of reperfusion
as an early index of myocardial infarct size. B, Left ventric-
ular systolic function, represented as fractional shortening (%),
was determined 7 days following the reperfusion. Data
are meansSD of n=6 to 10 animals. *P≤0.05 vs Sham,
#P≤0.05 vs IR. IPC indicates ischemic preconditioning; IPoC,
ischemic postconditioning; IR, ischemia/reperfusion.
Table 2. Functional Data Were Assessed Ex Vivo in a Working
Heart Model
Heart Rate (beats/min)
Baseline ISO
Sham 27229 34134*
IR 27648 36432*
IPC 26322 35272*
IPoC 27325 34741*
Coronary Flow (mL/min)
Baseline ISO
Sham 186 3011*
IR 155 227*
IPC 154 237*
IPoC 135 187*
Cardiac Output (mL/min)
Baseline ISO
Sham 487 666*
IR 368† 5112*
IPC 429 5411*
IPoC 3310† 3815
LVDP (kPa)
Baseline ISO
Sham 151 193*
IR 122† 172*
IPC 132† 163*
IPoC 122† 132
dP/dtmax (kPa/s)
Baseline ISO
Sham 61258 986251*
IR 468148† 876214*
IPC 515134 872207*
IPoC 445114† 607186*
Seven days after the myocardial infarction, cardiac function and hemodynamics were
recorded ﬁrst at a basal level and then 5 minutes after stimulation with ISO (10 nmol/L).
dP/dtmax indicates rate of pressure rise; IPC, ischemic preconditioning; IPoC, ischemic
postconditioning; IR, ischemia/reperfusion; ISO, isoproterenol; LVDP, left ventricular
developed pressure. Data are meansSD of n=6 to 10 hearts.
*P≤0.05 vs baseline.
†P≤0.05 vs Sham.
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The Mdm2 expression did not differ across the 4 treatment
groups, but its phosphorylated fraction was signiﬁcantly
reduced in the IR and IPC groups compared with the sham
group. In the IPoC hearts the phosphorylated fraction was
signiﬁcantly higher than that in the IR and IPC groups and did
not differ from the hearts of the sham group (Figure 7A
through 7C).
In the current study, induction or normalization of the
phosphoinositide 3-kinase (PI3 kinase) (Figure 7D and 7E)
was detected in IPoC hearts. Because PI3 kinase and Mdm2
have already been described as directly interacting partners,
the PI3 kinase/Akt/Mdm2 signaling pathway should be
primarily responsible for stabilizing the GRK2 in the hearts
of the IPoC group.30
Discussion
The development of contractile dysfunction as a conse-
quence of a myocardial infarction is often unavoidable, even
after successful reperfusion. The reduction in the size of the
infarct and metabolic disorder by applying IPC or IPoC
should also enable positive functional and structural remod-
eling over the long term based on an improved initial short-
term situation.
The key ﬁnding of this study is that, unlike ischemic
preconditioning, ischemic postconditioning does not lead to
functional preservation of the postischemic myocardium over
the long term, despite having short-term cardioprotective
potential.
Figure 5. Expression pattern of b-ARs. A, Representative immunoblots and densitometric analysis of (B) the b1-AR, (C) the b2-AR and (D) the
b3-AR. Remodeling and intracellular coupling of cardiac b-ARs. E, Representative blots and densitometric data of the (F) phosphorylated and (G)
total GRK2 protein. H, The pGRK2 to b1-AR ratio was calculated for each animal, and group means were expressed as fold change of Sham. I, The
mRNA expression of GRK2 was analyzed in left ventricular tissue and normalized to HPRT. J, b-Arrestin1/2, also critically involved in b-AR coupling,
was exclusively upregulated in IPoC hearts. K, Na+/K+ ATPase was determined as a surrogate marker for themembrane density. Immunoblot bands
were normalized to GAPDH and expressed as a percentage of Sham. Data are meansSD of n=6 hearts. *P≤0.05 vs Sham, #P≤0.05 vs IR. AR
indicates adrenergic receptor; arr, arrestin; GAPDH, Glyceraldehyde 3-phosphate dehydrogenase; GRK2, G protein-coupled receptor kinase 2;
HPRT, hypoxanthine-guanine phosphoribosyltransferase; IPC, ischemic preconditioning; IPoC, ischemic postconditioning; IR, ischemia/
reperfusion; p-GRK2, phosphorylated GRK2.
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Just 2 hours after the start of the reperfusion, the
intracellular coupling of the b1 receptor via ampliﬁed
phosphorylation of GRK2 was weakened by application of
IPoC. In the long term the speciﬁc induction/phosphoryla-
tion of GRK2 combined with the reduced expression of b-
ARs caused molecular remodeling in the postconditioned
heart, which, as a pathophysiological correlate of a contrac-
tile functional disorder, characterizes the start of systolic
heart failure. IPoC-induced desensitization of the b-receptors
only affected the myocardium, however, and thus only
reduced the rate of pressure rise and the positive inotropic
potential of the ventricle. The pacemaker cells were not
affected by the application, meaning that a (desirable)
frequency control was not observed. Apart from a desensi-
tization, the coronary vessels were also able to continue
ensuring myocardial perfusion as required thanks to the
preservation of the b-adrenergic-receptor-mediated vasodila-
tion.
At the moment it is largely unclear to what extent the
conditioned heart also beneﬁts over the long term from 1 of
the 2 protective strategies and to what extent receptor-
mediated signaling is affected by the 2 strategies. However,
effective use of therapy/medication following IPC or IPoC
assumes a well-founded understanding of the receptor status
of the conditioned postischemic heart.31
The ratio of b1 to b2 receptors is about 70:30 in the heart.
Functionally, their effect is primarily synergistic, but the b1
receptor has a greater effect on the myocardium, whereas the
b2 receptor has a greater effect on the smooth muscle cells of
the vessels. Quantitatively, the b3-AR plays a subordinate role
Figure 6. Remodeling of b-ARs as the main cause for the loss of the inotropic reserve in IPoC hearts. A,
Responsivity of cardiomyocytes isolated from IPC or IPoC hearts to ISO was analyzed using a cell-edge
detection system. B, Induction of GRK2 varied depending on whether IPC or IPoC was applied. Data are
meansSD of n=4 hearts/216 cells. *P≤0.05 vs IPC. IPoC-induced loss of the b-adrenergic functional
reserve. C, IPoC hearts 7 days after an infarction were perfused using the working heart technique. After
10 minutes’ infusion with paroxetine, the CO was measured continuously for 5 minutes with additional
stimulation using ISO. Data are meansSD of n=4 hearts. *P≤0.05 vs ISO. AR indicates adrenergic
receptor; CO, cardiac output; GAPDH, Glyceraldehyde 3-phosphate dehydrogenase; GRK2, G protein-
coupled receptor kinase 2; IPC, ischemic preconditioning; IPoC, ischemic postconditioning; ISO,
isoprenaline; Parox, paroxetine; p-GRK2, phosphorylated GRK2.
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in the heart, but protective effects are attributed to it,
particularly in the insufﬁcient myocardium.32
No change in the protein concentration of the b1 receptor
was recorded during the 2-hour reperfusion ex vivo. The
signiﬁcantly reduced proportion of receptor dimers indicates,
however, that remodeling of the b-adrenergic signaling has
already occurred during this short period independent of the 2
intervention strategies. A reduction in the receptor dimers in
turn leads to a lessening of the signal transduction and to
accelerated receptor internalization.33-36
The in vivo protocol used led to a signiﬁcant reduction in
the b1- and b2-AR subtypes, with the expression of the b3-AR
remaining stable, in the left ventricular myocardium in the IR,
IPC, and IPoC hearts 7 days after the infarction.
The effect on the intracellular coupling varied depending on
whether IPC or IPoC was used. The response of the
postconditioned left ventricular myocardium to a b-adrenergic
stimulus was signiﬁcantly reduced toward all comparator
groups. Selective increases in the GRK2 protein and its
phosphorylated fraction in the heart of the IPoC group were
identiﬁed as the cause.
It was originally postulated that an elevation in the GRK2
level during the progression of heart failure may be a sensible
protective mechanism that protects the heart against exces-
sive exposure to catecholamines.37 For the postinfarcted
heart, rapid and transient elevation or activation of the GRK2
could reduce the reperfusion injury and protect the myocar-
dium against hypercontractions. This mechanism may be
causally involved in the initial trend toward improved recovery
of postconditioned hearts compared with the IR and IPC
groups in the Langendorff model. At the start of the
reperfusion the IPoC-induced phosphorylation of GRK2 by
CEC could be signiﬁcantly reduced, and consequently the ISO-
induced increase in the LVDP can be reestablished. Conse-
quently, the activation of GRK2 should also be a PKC-
dependent process in the reperfused myocardium as well.
A sustained and long-term upregulation of GRK2 with the
resultant desensitization or uncoupling of cardiac receptors
leads inevitably to impaired cardiac function and loss of the
positive inotropic reserve.38-40 In a transgenic mouse model, a
cardiac-speciﬁc overexpression of the GRK2 inhibitor bARKct
not only improved the basal and catecholamine-stimulated
Figure 7. Regulatory mechanisms for GRK2. A, Representative immunoblots and densitometric data of
the (B) phosphorylated and (C) total MDM2 protein. D, Western blot image and (E) analysis of PI3 kinase
expression. Immunoblot bands were normalized to GAPDH and expressed as a percentage of Sham. Data
are meansSD of n=6 hearts. *P≤0.05 vs Sham, #P≤0.05 vs IR. GAPDH indicates Glyceraldehyde 3-
phosphate dehydrogenase; GRK2, G protein–coupled receptor kinase 2; IPC, ischemic preconditioning;
IPoC, ischemic postconditioning; IR, ischemia/reperfusion; MDM2, mouse double minute 2 homolog/E3
ubiquitin-protein ligase Mdm2; p-GRK2, phosphorylated GRK2; PI3K, phosphoinositide 3-kinase; p-MDM2,
phosphorylated MDM2.
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heart function, it also led to a signiﬁcant reduction in cardiac
dysfunction andmortality in variousmodels of heart failure.41-43
These results were conﬁrmed by using cardiac-speciﬁc
heterozygous GRK2 knockout mice that also had a signiﬁcantly
better prognosis after induction of heart failure.44
Particularly when considering the early cardioprotective
effects that can be achieved by the postconditioning protocol
used here, the importance of desensitized or uncoupled b-ARs
becomes clear because, along with the loss of their
b-adrenergic contraction reserve, IPoC hearts have the worst
heart function at rest measured using echocardiography after
7 days have elapsed.
At this point there are only a few veriﬁed ﬁndings for the
precise regulatory mechanisms for GRK2 within the cardio-
vascular system. The expression is controlled both at the level
of the transcription and by affecting the degradation and thus
the stabilization of the protein.45 The precise interplay
between synthesis and degradation under physiological and
pathophysiological conditions is largely unknown, but ubiqui-
tination with subsequent proteasomal degradation is consid-
ered to play a signiﬁcant role in the degradation of GRK2.46
Both b-arrestin and the E3-ubiquitin ligase Mdm2 are also
involved in this process, initiating the degradation of GRK2 by
the proteasome by forming a complex.47 Various functions are
attributed to b-arrestin as part of the regulatory mechanisms
that underlie the receptor coupling or desensitization.
Together with GRK2, it is directly involved in the uncoupling
and internalization of G-protein-coupled receptors. Further-
more, in the absence of receptor stimulation, it can inhibit
GRK2-Mdm2 interaction and thus the degradation of GRK2,
but if the receptor is stimulated, it can boost complex
formation and thus the degradation of GRK2.48
Based on the present results, the signiﬁcant increase in
GRK2 levels in IPoC hearts can be ascribed to impaired
degradation that is caused by increased phosphorylation of
Mdm2. Phosphorylated Mdm2 translocates increasingly into
the nucleus and is thus no longer available for ubiquitination
of GRK2 in the cytosol. It is also postulated that the
interaction between phosphorylated Mdm2 and GRK2 is
impaired, and subsequently, the complex cannot be trans-
ported to the proteasome.47
PI3 kinase and Akt have already been identiﬁed as direct
upstreamelements ofMdm2and are considered responsible for
its phosphorylation.30,49,50 The induction of both PI3 kinase and
Akt plays a crucial role in cardioprotection during IPoC and is
classiﬁed as a key element of the prosurvival RISK pathway.51,52
The functional effects of a pharmacological GRK2 inhibition
could be demonstrated in both isolated cardiomyocytes and in
the isolated, perfused heart. In the IPoC heart, the CO could
only be signiﬁcantly elevated by b-adrenergic stimulation with
selective inhibition of GRK2. These ﬁndings emphasize not
only the importance of GRK2 for cardiac function, they also
identify GRK2 as the reason for the loss of inotropic functional
reserve of the postconditioned myocardium. GRK2 is currently
being considered as a therapeutic target for chronic heart
failure.53 Along with the cardioprotective potential immediately
after the start of reperfusion, selective inhibition of GRK2 could
also achieve signiﬁcant functional improvement in the post-
conditioned myocardium over the long term (Figure 8).
In summary, the results of this study demonstrate for the
ﬁrst time that the application of IPoC induces desensitization
or uncoupling of b-ARs, which leads to induction of cardiac
dysfunction with a restricted inotropic functional reserve. With
comparable cardioprotective properties immediately after
acute myocardial infarction, IPC also ensures that the function
of the postischemic myocardium is preserved over the long
term without exerting a negative effect on the b-adrenergic
system. The present results must be considered a possible
reason behind the disappointing results obtained in longitu-
dinal clinical studies to date and should lead to a critical
review of the clinical use of IPoC.
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3-kinase; PKC, protein kinase C.
DOI: 10.1161/JAHA.117.006809 Journal of the American Heart Association 14
Postischemic Remodeling of b-Adrenergic Coupling Schreckenberg et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
Ferdinandy was a Szentagothai Fellow of the National
Program of Excellence (Grant TAMOP 4.2.4.A/2-11-1-2012-
0001).
Disclosures
None.
References
1. Hausenloy DJ, Yellon DM. Survival kinases in ischemic preconditioning and
postconditioning. Cardiovasc Res. 2006;70:240–253.
2. Zhao ZQ, Corvera JS, Halkos ME, Kerendi F, Wang NP, Guyton RA, Vinten-
Johansen J. Inhibition of myocardial injury by ischemic postconditioning during
reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ
Physiol. 2003;285:H579–H588.
3. Heusch G. Molecular basis of cardioprotection: signal transduction in ischemic
pre-, post-, and remote conditioning. Circ Res. 2015;116:674–699.
4. van Vuuren D, Genis A, Genade S, Lochner A. Postconditioning the isolated
working rat heart. Cardiovasc Drugs Ther. 2008;22:391–397.
5. Couvreur N, Lucats L, Tissier R, Bize A, Berdeaux A, Ghaleh B. Differential
effects of postconditioning on myocardial stunning and infarction: a study in
conscious dogs and anesthetized rabbits. Am J Physiol Heart Circ Physiol.
2006;291:H1345–H1350.
6. Staat P, Rioufol G, Piot C, Cottin Y, Cung TT, L’Huillier I, Aupetit JF, Bonnefoy E,
Finet G, Andre-Fou€et X, Ovize M. Postconditioning the human heart.
Circulation. 2005;112:2143–2148.
7. Granfeldt A, Lefer DJ, Vinten-Johansen J. Protective ischaemia in patients:
preconditioning and postconditioning. Cardiovasc Res. 2009;83:234–246.
8. Hausenloy DJ, Erik Bøtker H, Condorelli G, Ferdinandy P, Garcia-Dorado D,
Heusch G, Lecour S, van Laake LW, Madonna R, Ruiz-Meana M, Schulz R,
Sluijter JP, Yellon DM, Ovize M. Translating cardioprotection for patient
beneﬁt: position paper from the Working Group of Cellular Biology of the Heart
of the European Society of Cardiology. Cardiovasc Res. 2013;98:7–27.
9. Freixa X, Bellera N, Ortiz-Perez JT, Jimenez M, Pare C, Bosch X, De Caralt TM,
Betriu A, Masotti M. Ischaemic postconditioning revisited: lack of effects on
infarct size following primary percutaneous coronary intervention. Eur Heart J.
2012;33:103–112.
10. Hahn JY, Yu CW, Park HS, Song YB, Kim EK, Lee HJ, Bae JW, Chung WY, Choi
SH, Choi JH, Bae JH, An KJ, Park JS, Oh JH, Kim SW, Hwang JY, Ryu JK, Lim DS,
Gwon HC. Long-term effects of ischemic postconditioning on clinical
outcomes: 1-year follow-up of the POST randomized trial. Am Heart J.
2015;169:639–646.
11. Engstrøm T, Kelbæk H, Helqvist S, Høfsten DE, Kløvgaard L, Clemmensen P,
Holmvang L, Jørgensen E, Pedersen F, Saunamaki K, Ravkilde J, Tilsted HH,
Villadsen A, Aarøe J, Jensen SE, Raungaard B, Bøtker HE, Terkelsen CJ, Maeng
M, Kaltoft A, Krusell LR, Jensen LO, Veien KT, Kofoed KF, Torp-Pedersen C,
Kyhl K, Nepper-Christensen L, Treiman M, Vejlstrup N, Ahtarovski K, Lønborg J,
Køber L; Third Danish Study of Optimal Acute Treatment of Patients With ST
Elevation Myocardial Infarction–Ischemic Postconditioning (DANAMI-3–iPOST)
Investigators. Effect of ischemic postconditioning during primary percuta-
neous coronary intervention for patients with ST-segment elevation myocardial
infarction: a randomized clinical trial. JAMA Cardiol. 2017;2:490–497.
12. Ferdinandy P, Schulz R, Baxter GF. Interaction of cardiovascular risk factors
with myocardial ischemia/reperfusion injury, preconditioning, and postcondi-
tioning. Pharmacol Rev. 2007;59:418–458.
13. Lecour S, Bøtker HE, Condorelli G, Davidson SM, Garcia-Dorado D, Engel FB,
Ferdinandy P, Heusch G, Madonna R, Ovize M, Ruiz-Meana M, Schulz R,
Sluijter JP, Van Laake LW, Yellon DM, Hausenloy DJ. ESC working group
cellular biology of the heart: position paper: improving the preclinical
assessment of novel cardioprotective therapies. Cardiovasc Res.
2014;104:399–411.
14. Ferdinandy P, Hausenloy DJ, Heusch G, Baxter GF, Schulz R. Interaction of risk
factors, comorbidities, and comedications with ischemia/reperfusion injury
and cardioprotection by preconditioning, postconditioning, and remote
conditioning. Pharmacol Rev. 2014;66:1142–1174.
15. Schreckenberg R, Maier T, Schl€uter KD. Post-conditioning restores pre-
ischaemic receptor coupling in rat isolated hearts. Br J Pharmacol.
2009;156:901–908.
16. White DC, Hata JA, Shah AS, Glower DD, Lefkowitz RJ, Koch WJ. Preservation of
myocardial b-adrenergic receptor signaling delays the development of heart
failure after myocardial infarction. Proc Natl Acad Sci USA. 2000;97:5428–
5433.
17. Anthonio RL, Brodde OE, van Veldhuisen DJ, Scholtens E, Crijns HJ, van Gilst
WH. b-Adrenoceptor density in chronic infarcted myocardium: a subtype
speciﬁc decrease of b1-adrenoceptor density. Int J Cardiol. 2000;72:137–141.
18. Strasser RH, Marquetant R. Sensitization of the beta-adrenergic system in
acute myocardial ischaemia by a protein kinase C-dependent mechanism. Eur
Heart J. 1991;12:48–53.
19. Nazarewicz RR, Bikineyeva A, Dikalov SI. Rapid and speciﬁc measurements of
superoxide using ﬂuorescence spectroscopy. J Biomol Screen. 2013;18:498–
503.
20. Bencsik P, Kupai K, Giricz Z, G€orbe A, Pipis J, Murlasits Z, Kocsis GF, Varga-
Orvos Z, Puskas LG, Csonka C, Csont T, Ferdinandy P. Role of iNOS and
peroxynitrite-matrix metalloproteinase-2 signaling in myocardial late precon-
ditioning in rats. Am J Physiol Heart Circ Physiol. 2010;299:H512–H518.
21. Bencsik P, Paloczi J, Kocsis GF, Pipis J, Belecz I, Varga ZV, Csonka C, G€orbe A,
Csont T, Ferdinandy P. Moderate inhibition of myocardial matrix metallopro-
teinase-2 by ilomastat is cardioprotective. Pharmacol Res. 2014;80:36–42.
22. Kocsis GF, Sark€ozy M, Bencsik P, Pipicz M, Varga ZV, Paloczi J, Csonka C,
Ferdinandy P, Csont T. Preconditioning protects the heart in a prolonged
uremic condition. Am J Physiol Heart Circ Physiol. 2012;303:H1229–H1236.
23. Neely JR, Liebermeister H, Battersby EJ, Morgan HE. Effect of pressure
development on oxygen consumption by isolated rat heart. Am J Physiol.
1967;212:804–814.
24. Ferdinandy P, Szilvassy Z, Csont T, Csonka C, Nagy E, Koltai M, Dux L.
Nitroglycerin-induced direct protection of the ischaemic myocardium in
isolated working hearts of rats with vascular tolerance to nitroglycerin. Br J
Pharmacol. 1995;115:1129–1131.
25. Ferdinandy P, Csonka C, Csont T, Szilvassy Z, Dux L. Rapid pacing-induced
preconditioning is recaptured by farnesol treatment in hearts of cholesterol-
fed rats: role of polyprenyl derivatives and nitric oxide. Mol Cell Biochem.
1998;186:27–34.
26. Csonka C, Kupai K, Kocsis GF, Novak G, Fekete V, Bencsik P, Csont T,
Ferdinandy P. Measurement of myocardial infarct size in preclinical studies. J
Pharmacol Toxicol Methods. 2010;61:163–170.
27. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-
time quantitative PCR and the 2(–DDC(T)). Methods. 2001;25:402–408.
28. Tastan I, Schreckenberg R, Mufti S, Abdallah Y, Piper HM, Schl€uter KD.
Parathyroid hormone improves contractile performance of adult rat ventricular
cardiomyocytes at low concentrations in a non-acute way. Cardiovasc Res.
2009;82:77–83.
29. Krasel C, Dammeier S, Winstel R, Brockmann J, Mischak H, Lohse MJ.
Phosphorylation of GRK2 by protein kinase C abolishes its inhibition by
calmodulin. J Biol Chem. 2001;276:1911–1915.
30. Mayo LD, Donner DB. A phosphatidylinositol 3-kinase/Akt pathway promotes
translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci
USA. 2001;98:11598–11603.
31. Ovize M, Baxter GF, Di Lisa F, Ferdinandy P, Garcia-Dorado D, Hausenloy DJ,
Heusch G, Vinten-Johansen J, Yellon DM, Schulz R. Postconditioning and
protection from reperfusion injury: where do we stand? Cardiovasc Res.
2010;87:406–423.
32. Niu X, Watts VL, Cingolani OH, Sivakumaran V, Leyton-Mange JS, Ellis CL,
Miller KL, Vandegaer K, Bedja D, Gabrielson KL, Paolocci N, Kass DA, Barouch
LA. Cardioprotective effect of beta-3 adrenergic receptor agonism: role of
neuronal nitric oxide synthase. J Am Coll Cardiol. 2012;59:1979–1987.
33. Lan TH, Kuravi S, Lambert NA. Internalization dissociates b2-adrenergic
receptors. PLoS One. 2011;6:e17361.
34. He J, Xu J, Castleberry AM, Lau AG, Hall RA. Glycosylation of beta(1)-adrenergic
receptors regulates receptor surface expression and dimerization. Biochem
Biophys Res Commun. 2002;297:565–572.
35. Hebert TE, Moffett S, Morello JP, Loisel TP, Bichet DG, Barret C, Bouvier M. A
peptide derived from a beta2-adrenergic receptor transmembrane domain
inhibits both receptor dimerization and activation. J Biol Chem.
1996;271:16384–16392.
36. Kobayashi H, Ogawa K, Yao R, Lichtarge O, Bouvier M. Functional rescue of b1-
adrenoceptor dimerization and trafﬁcking by pharmacological chaperones.
Trafﬁc. 2009;10:1019–1033.
37. Matkovich SJ, Diwan A, Klanke JL, Hammer DJ, Marreez Y, Odley AM, Brunskill
EW, Koch WJ, Schwartz RJ, Dorn GW II. Cardiac-speciﬁc ablation of G-protein
receptor kinase 2 redeﬁnes its roles in heart development and b-adrenergic
signaling. Circ Res. 2006;99:996–1003.
38. Koch WJ, Rockman HA, Samama P, Hamilton RA, Bond RA, Milano CA,
Lefkowitz RJ. Cardiac function in mice overexpressing the beta-adrenergic
receptor kinase or a beta ARK inhibitor. Science. 1995;268:1350–1353.
DOI: 10.1161/JAHA.117.006809 Journal of the American Heart Association 15
Postischemic Remodeling of b-Adrenergic Coupling Schreckenberg et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
39. Lymperopoulos A. GRK2 and b-arrestins in cardiovascular disease: something
old, something new. Am J Cardiovasc Dis. 2011;1:126–237.
40. Raake PW, Zhang X, Vinge LE, Brinks H, Gao E, Jaleel N, Li Y, Tang M, Most P,
Dorn GW II, Houser SR, Katus HA, Chen X, Koch WJ. Cardiac G-protein-coupled
receptor kinase 2 ablation induces a novel Ca2+ handling phenotype resistant
to adverse alterations and remodeling after myocardial infarction. Circulation.
2012;125:2108–2118.
41. Tevaearai HT, Walton GB, Keys JR, Koch WJ, Eckhart AD. Acute ischemic
cardiac dysfunction is attenuated via gene transfer of a peptide inhibitor
of the b-adrenergic receptor kinase (bARK1). J Gene Med. 2005;7:1172–
1177.
42. Harding VB, Jones LR, Lefkowitz RJ, Koch WJ, Rockman HA. Cardiac bARK1
inhibition prolongs survival and augments b-blocker therapy in a
mouse model of severe heart failure. Proc Natl Acad Sci USA.
2001;98:5809–5814.
43. Siryk-Bathgate A, Dabul S, Lymperopoulos A. Current and future G protein-
coupled receptor signaling targets for heart failure therapy. Drug Des Devel
Ther. 2013;7:1209–1222.
44. Rockman HA, Choi DJ, Akhter SA, Jaber M, Giros B, Lefkowitz RJ, Caron MG,
Koch WJ. Control of myocardial contractile function by the level of beta-
adrenergic receptor kinase 1 in gene-targeted mice. J Biol Chem.
1998;273:18180–18184.
45. Penela P, Murga C, Ribas C, Tutor AS, Peregrın S, Mayor F Jr. Mechanisms of
regulation of G protein-coupled receptor kinases (GRKs) and cardiovascular
disease. Cardiovasc Res. 2006;69:46–56.
46. Penela P, Ruiz-Gomez A, Casta~no JG, Mayor F Jr. Degradation of the G protein-
coupled receptor kinase 2 by the proteasome pathway. J Biol Chem.
1998;273:35238–35244.
47. Salcedo A, Mayor F Jr, Penela P. Mdm2 is involved in the ubiquitination and
degradation of G-protein-coupled receptor kinase 2. EMBO J. 2006;25:4752–
4762.
48. Nogues L, Salcedo A, Mayor F Jr, Penela P. Multiple scaffolding functions of
{beta}-arrestins in the degradation of G protein-coupled receptor kinase 2. J
Biol Chem. 2011;286:1165–1173.
49. Feng J, Tamaskovic R, Yang Z, Brazil DP, Merlo A, Hess D, Hemmings BA.
Stabilization ofMdm2 via decreased ubiquitination ismediated by protein kinase
B/Akt-dependent phosphorylation. J Biol Chem. 2004;279:35510–35517.
50. Ogawara Y, Kishishita S, Obata T, Isazawa Y, Suzuki T, Tanaka K, Masuyama N,
Gotoh Y. Akt enhances Mdm2-mediated ubiquitination and degradation of
p53. J Biol Chem. 2002;277:21843–21850.
51. Tsang A, Hausenloy DJ, Mocanu MM, Yellon DM. Postconditioning: a form of
“modiﬁed reperfusion” protects the myocardium by activating the phos-
phatidylinositol 3-kinase-Akt pathway. Circ Res. 2004;95:230–232.
52. Zhu M, Feng J, Lucchinetti E, Fischer G, Xu L, Pedrazzini T, Schaub MC, Zaugg
M. Ischemic postconditioning protects remodeled myocardium via the PI3K-
PKB/Akt reperfusion injury salvage kinase pathway. Cardiovasc Res.
2006;72:152–162.
53. Schumacher-Bass SM, Traynham CJ, Koch WJ. G protein-coupled receptor
kinase 2 as a therapeutic target for heart failure. Drug Discov Today Ther
Strateg. 2012;9:155–162.
DOI: 10.1161/JAHA.117.006809 Journal of the American Heart Association 16
Postischemic Remodeling of b-Adrenergic Coupling Schreckenberg et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
SUPPLEMENTAL MATERIAL
Sham IR IPC IPoC 
FS (%) 59.8±11.9 42.9±10.3* 49.8±13.9 32.2±12.0* 
IVSd (mm) 1.65±0.50 1.74±0.32 1.83±0.40 1,52±0.23 
LVPWd (mm) 1.62±0.37 1.84±0.22 1.90±0.34 1.86±0.32 
LVPWs (mm) 2.53±0.34 2.71±0.44 2.86±0.47 2.61±0.60 
LVIDd (mm) 5.25±0.89 5.75±1.28 5.52±0.94 6.03±0.58 
LVIDs (mm) 2.69±1.32 3.23±0.90 2.88±1.10 3.43±0.63 
 FS (%): fractional shortening, IVSd (mm): end-diastolic interventricular septum thickness, 
LVPWd (mm): left ventricular posterior wall thickness in diastole, LVPWs (mm): left 
ventricular posterior wall thickness in systole, LVIDd (mm): left ventricular internal diameter 
in diastole, LVIDs (mm): left ventricular internal diameter in systole. Data are means 
 S.D. of n=6-10 animals. *, p≤0.05 vs. Sham.
Table S1. Functional and morphological data assessed by echocardiography.
Plasma TnI values that were measured one hour after the start of the reperfusion confirm a 
reduction of the particular size of the infarct to the same magnitude as determined using TTC 
staining two hours after the start of the reperfusion. Data are means  S.D. of n=6 hearts. *, 
p≤0.05 vs. IR. 
Figure S1. The validity of TnI as a marker to determine the infarct size. 
A-C) The mRNA expression of the β1- and β2-AR subtypes was reduced in the hearts in the 
IR, IPC and IPoC groups compared to the sham group seven days after the infarction. 
However, the expression of the β3-AR remained stable and was unaffected by either IPC or 
IPoC. Data are means  S.D. of n=6 hearts. *, p≤0.05 vs. Sham. 
Figure S2. Expression pattern of β-ARs in left ventricular tissue.
The importance of GRK2 and β-arrestin for the β-AR–mediated positive inotropic response of 
the myocardium was investigated using a model of left ventricular cardiomyocytes isolated 
from three-month-old Wistar rats. GRK2, β-arrestin 1  
Figure S3. The effect of GRK2 and β-arrestin on the contraction of isolated ventricular 
cardiomyocytes. 
and β-arrestin 2 were selectively and effectively downregulated by transfection with siRNA 
over 24 hours (Fig ure S6A,B). The load free cell shortening before and after stimulation with 
ISO was then determined. A) In untreated cardiomyocytes ISO improved basal cell 
shortening by 45±9%. Cardiomyocytes in which the GRK2 was        previously downregulated 
were sensitised to the  β-adrenergic stimulus and showed an improvement in the cell 
shortening of about 70 ±15%. B) Specifically knocking down the β-arrestin 1 isoform 
improved the ISO-induced cell shortening by 57±12% while the β-adrenergic stimulation after 
successful knockdown of β-arrestin 2 did not differ significantly from ISO treated cells.  
Transfection of the cardiomyocytes with nonsense siRNA over 24 hours did not have any 
effect on cell shortening.  C) The use of GRK2-specific siRNA was supplemented in the cell 
culture model described above by application of the selective GRK2 inhibitor paroxetine. After 
a 15-minute pre-incubation with paroxetine, the ISO-induced increase in cell shortening 
increased in a concentration-dependent manner from  55±8% to 79±12% (1 µM) and to 117
±22% (5 µM). Data are means  S.D. of n=3 hearts. *, p≤0.05 vs. Control, #, p≤0.05 vs. ISO. 
Using the Langendorff technique, rat hearts were initially perfused for 10 min with paroxetine 
and then stimulated for a further 5 min with ISO in the presence of paroxetine. Hearts that 
had not had their GRK2 inhibited responded to the β-adrenergic stimulation with an increase 
in the LVDP of 30±20% while the LVDP of hearts perfused with paroxetine increased by 71
±51%. Data are means  S.D. of n=4 hearts. *, p≤0.05 vs. ISO. 
Figure S4. The functional relevance of GRK2 in ex-vivo perfused hearts. 
Left ventricular cardiomyocytes isolated from three-month-old Wistar rats were used to 
determine the ISO concentration used in all experiments to measure the β-AR–mediated 
positive inotropic response. The ISO-induced increase in cell shortening increased in a 
concentration-dependent, however, concentrations above 10 nM had no further effects. Data 
are means  S.D. of n=3 hearts. *, p≤0.05 vs. Control, #, p≤0.05 vs. ISO 1 nM. 
Figure S5. Concentration – response curves to isoprenaline (ISO) in isolated cardiomyocytes. 
A-B) Representative immunoblots and densitometric analysis: the expression of GRK2 (A),
β-arrestin1 and β-arrestin2 (B) was analysed 24 hours after transfection of isolated 
cardiomyocytes. Data are means  S.D. of n=3 hearts. *, p≤0.05 vs. Control. 
Figure S6. Western blot analysis to assess the efficiency of the siRNA-mediated knockdown. 
